A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US

Completed

Conditions studied: Melanoma

In brief

The goal of this study is to describe patient characteristics, treatment outcomes and adverse events for patients with metastatic melanoma testing positive for PD-L1 expression treated first line (1L) with either nivolumab and ipilimumab in combination (NIVO + IPI) or nivolumab (NIVO) monotherapy

Key facts

Study ID

NCT03732560

Run by

Bristol-Myers Squibb

People needed

600

Starts

2018-07-31

Expected to finish

2021-03-25

Last updated by the study team

2022-12-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults 18 years or older
• First advanced of diagnosis of metastatic/Stage IV) melanoma
• Tested for PD-L1 expression with a tumor proportion score (TPS) greater than or equal to 1% (Phase 1 data collection)
• Initiating a first line of therapy during the index period between October 1, 2015 through July 1, 2017
• Medical history available for medical chart abstraction from date of diagnosis through most recent or current therapy (defined as end of data collection period)

You may not qualify if…

• Patients enrolled in a cancer treatment-related clinical trial prior to first line therapy initiation for metastatic/Stage IV) melanoma
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• Local Institution — Parsippany, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.